PWMG
LGND icon

Prestige Wealth Management Group’s Ligand Pharmaceuticals LGND Stock Holding History

Prestige Wealth Management Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949 Buy
3
+1
+50% +$236 ﹤0.01% 923
2026
Q1 		$400 Buy
+2
New +$396 ﹤0.01% 991
2019
Q1 		– Sell
-8
Closed -$1K – 853
2018
Q4 		$1K Buy
+8
New +$853 ﹤0.01% 1059

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prestige Wealth Management Group's LGND Position: Q2 2026 in Review

Prestige Wealth Management Group increased its Ligand Pharmaceuticals (LGND) stake by 50% in Q2 2026, buying an estimated $236 and bringing the position to 3 shares worth $949. The position accounts for ﹤0.01% of the portfolio, ranked #923.

Prestige Wealth Management Group first reported a position in LGND in Q4 2018 and has held it in 3 quarters since. The position peaked at $1K in Q4 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Prestige Wealth Management Group held 3 shares of Ligand Pharmaceuticals worth $949 as of Q2 2026.
  • Prestige Wealth Management Group bought 1 Ligand Pharmaceuticals share in Q2 2026, an estimated $236.
  • Ligand Pharmaceuticals made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #923 holding.
  • Prestige Wealth Management Group first reported a position in Ligand Pharmaceuticals in Q4 2018 and has held it in 3 quarters since.
  • Prestige Wealth Management Group's Ligand Pharmaceuticals position peaked at $1K in Q4 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.